Updating results

478 results

Sort: Relevance | Date

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2019)

In development [GID-NG10087] Expected publication date: 30 March 2020

NICE guideline In development

Insect bites and stings: antimicrobial prescribing

In development [GID-NG10136] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

In development [GID-NG10110] Expected publication date: 07 April 2021

NICE guideline In development

Postnatal care

In development [GID-NG10070] Expected publication date: 25 November 2020

NICE guideline In development

Atrial fibrillation: management

In development [GID-NG10100] Expected publication date: 17 September 2020

NICE guideline In development

Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 28 May 2021

NICE guideline In development

Perioperative care in adults

In development [GID-NG10072] Expected publication date: 27 May 2020

NICE guideline In development

Tobacco: preventing uptake, promoting quitting and treating dependence (update)

In development [GID-NG10086] Expected publication date: 18 January 2021

NICE guideline In development

Behaviour change: digital and mobile health interventions

In development [GID-NG10101] Expected publication date: 05 August 2020

NICE guideline In development

Joint replacement (primary): hip, knee and shoulder

In development [GID-NG10084] Expected publication date: 25 March 2020

NICE guideline In development

Looked-after children and young people

In development [GID-NG10121] Expected publication date: 26 April 2021

NICE guideline In development

Neonatal infection (early onset): antibiotics for prevention and treatment

In development [GID-NG10111] Expected publication date: 05 March 2021

NICE guideline In development

Reducing sexually transmitted infections

In development [GID-NG10142] Expected publication date: 01 September 2021

NICE guideline In development

Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 19 October 2021

NICE guideline In development

Head injury: assessment and early management

In development [GID-NG10164] Expected publication date: 02 December 2021

NICE guideline In development

Abdominal aortic aneurysm: diagnosis and management

In development [GID-CGWAVE0769] Expected publication date: TBC

NICE guideline In development

Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management

In development [GID-NG10091] Expected publication date: 09 December 2020

NICE guideline In development

Obesity: identification, assessment and management

In development [GID-NG10157] Expected publication date: 23 June 2022

NICE guideline In development

Skin tumours including Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 04 April 2022

NICE guideline In development

Barrett's oesophagus: ablative therapy

In development [GID-NG10165] Expected publication date: 17 August 2022

NICE guideline In development

Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

In development [GID-NG10098] Expected publication date: 05 November 2020

NICE guideline In development

Multiple sclerosis in adults: management

In development [GID-NG10153] Expected publication date: 04 May 2022

NICE guideline In development

Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Technology appraisal guidance In development

Spasticity (after stroke) - botulinum toxin type A [ID768]

In development [GID-TAG499] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib for untreated mantle cell lymphoma (ID1221)

In development [GID-TA10185] Expected publication date: TBC

Technology appraisal guidance In development

Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

In development [GID-TA10179] Expected publication date: TBC

Technology appraisal guidance In development

NY-ESO-1 T-cells for treating synovial sarcoma ID1286

In development [GID-TA10205] Expected publication date: TBC

Technology appraisal guidance In development

ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203

In development [GID-TA10204] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

In development [GID-TA10223] Expected publication date: TBC

Technology appraisal guidance In development

Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Technology appraisal guidance In development

Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

In development [GID-TA10225] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

In development [GID-TA10210] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168

In development [GID-TA10208] Expected publication date: TBC

Technology appraisal guidance In development

Selumetinib for treating differentiated thyroid cancer ID1079

In development [GID-TA10207] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]

In development [GID-TA10209] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Technology appraisal guidance In development

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Technology appraisal guidance In development

Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Technology appraisal guidance In development

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Technology appraisal guidance In development

Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Technology appraisal guidance In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for untreated advanced gastric cancer [ID1465]

In development [GID-TA10352] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: TBC

Technology appraisal guidance In development

Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

In development [GID-TA10361] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Technology appraisal guidance In development

Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352

In development [GID-TA10319] Expected publication date: TBC

Technology appraisal guidance In development

Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Technology appraisal guidance In development